Bristol Myers Squibb (BMY) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Bristol Myers Squibb (BMY)

66.58

-0.37 (0.55%)

as of Aug 28, 2026, 8:00:00 pm Market Open.

162 watching

Investor Insights

Aug 30, 2026, 12:00 am

This summary was created by AI, based on 8 opinions in the last 12 months.

Bristol Myers Squibb (BMY) has garnered a mixed set of opinions from various analysts. Some reviewers highlight the company's strong performance in 2023, with a 19% increase in stock price and a robust free cash flow projected to hit $15 billion by 2027. The company is also noted for its attractive dividend yield exceeding 4% and a promising drug pipeline, which could support future growth. However, concerns have been raised regarding the disappointing sales of its Cobenfy drug, leading some experts to reassess their investment positions. Overall, there is a sense of cautious optimism about the potential for recovery if the growth portfolio can continue to outperform the legacy products.

Consensus

Mixed

Valuation

Undervalued

Similar

EliLilly,LLY

BUY

Doesn’t own any drug names currently. They’ve been value traps. Great dividend yield but not performing well because of generic. In the current market conditions the dividend is a good plus.

TOP PICK

Good yield, but also selling close to its absolute low since 1982. In the meantime everything is happily bubbling along for the company. Excellent upside potential. Partially defensive but also partly aggressive.

PAST TOP PICK

(A Top Pick April 6/10. Up 8.38%.) One of the few drug companies with a good pipeline. A medium size major so has room to grow. Recently got FDA approval for a cancer/melanoma drug. This could be a blockbuster drug.

COMMENT

A good company but prefers Johnson and Johnson (JNJ-N) for the longer term. Pays a good dividend. Strong franchise.

TOP PICK

Likes the US health care pharmaceuticals in general. This one has a nice yield. Selling at a low valuation.

PAST TOP PICK

(A Top Pick Jan 28/10. Up 13.26%.) People don’t like drug companies as many of them have patent cliffs where a lot of their big drugs are coming off patent. This one has a good pipeline of good and promising drugs.

TOP PICK

Good pipeline and a large amount of cash that can be used for acquisitions. Expects they will continue to raise their 4.8% dividend.

TOP PICK

Likes the healthcare area. Cheap compared to the rest of the market. Investors are starting to come into it realizing that negativity towards drug companies had been overdone. Built up a war chest of $3 billion. 5.25% yield.

DON'T BUY

Very cheap on any value metrics but has had a very hard time. Did very well when they had blockbuster drugs but those drugs have come off and it is hard to get them replaced. Prefers Johnson & Johnson (JNJ-N) because it is not a pure pharmaceutical company.

SELL

(Market Call Minute) A drug coming off Patent in 2012 represents 27% of revenues.

TOP PICK

In a trading range of about $22-$28. At $23 or lower it’s a Buy. 5.5% yield. Has a better pipeline of pharmaceutical products than a lot of other competitors. If you got it at these prices and that one up to $25-$26, he would pare it back.

TOP PICK

Likes the pharma space, which has been beaten up badly. What intrigues him is the pill popping baby boomers. Has one of the best profiles on patent expiries. Less than 6% dividend.

DON'T BUY

Not thrilled with the entire pharmaceutical industry.

BUY

(Market Call Minute.) Has a really good dividend yield and have got past their problems of patent expiries and regulatory issues.

HOLD

Pfizer (PFE-N) has a better product pipeline and a higher growth rate. Recently, the stock has been outperforming Pfizer. He thinks they are for sale and is waiting for the right partner to come along. If you own, hold on for the moment.

Showing 151 to 165 of 222 entries

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Jim Lebenthal

Cerity Partners

Bill Baruch, Founder, Blue Line Capital

Blue Line Capital

Brianne Gardner

Raymond James

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Bristol Myers Squibb (BMY)